FDA label
What is Copaxone used for?
Copaxone contains glatiramer acetate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Copaxone?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Copaxone, injection, solution
Indications and Usage, quoted from the label by Teva Neuroscience, Inc. (NDA020622). Cross-references to other label sections are left out.
COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: DailyMed label, set id aa88f583-4f5f-433b-80b4-1f4c9fb28357, version 36, effective June 23, 2026. NDC 68546-317, one of 2 listings for this product.
Questions
What is Copaxone used for?
The FDA label says: “COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Copaxone
- Is Copaxone a controlled substance?Federal schedule
- Generic for CopaxoneFDA Orange Book
- What is Glatiramer Acetate used for?FDA label uses
- Is Glatiramer Acetate a controlled substance?Federal schedule
- Copaxone Medicare Part D coverageBy plan and state
- NDC 68546-317Copaxone NDC record
- NDC 68546-325Copaxone NDC record